Bruce M. Psaty, MD, PhD, MPH

Professor

Medicine

Professor

Epidemiology

Adjunct Professor

Health Services

Co-director, Cardiovascular Health Research Unit

Faculty Information

Biography

Education & Training:

PhD, English language and literature

Indiana University

Bloomington, IN

1979

Indiana University, School of Medicine

Indianapolis, IN

1981

Residency in Internal Medicine

Indiana University Medical Center

Indianapolis, IN

1984

MPH

University of Washington

Seattle, WA

1986

Honors:

Remington Methodology Lecturer, AHA Epidemiology and Prevention Council

2004

School of Public Health and Community Medicine Outstanding Faculty Community Service Award

2005

University of Washington Outstanding Public Service Award for Work in Drug Safety

2005

Ancel Keys Memorial Lectureship, American Heart Association National Meeting

2009

Member, US Food and Drug Administration Science Board

2011–2018

Member, National Heart, Lung, Blood Institute Advisory Council

2012–2017

Designated Distinguished Scientist by the American Heart Association

2013

Elected to the Institute of Medicine of the National Academies of Science

2013

University of Washington, School of Public Health Distinguished Alumni Award

2018

Member, National Heart, Lung, and Blood Institute Board of External Experts

2018–

Contact

Email:

psaty@uw.edu [1]

Research & Clinical Interests

Research Interests:

Myocardial infarction, venous thrombosis, and stroke
Hypertension, hyperlipidemia, diabetes, and atrial fibrillation
Pharmacoepidemiology
Genetics, genomics, and pharmacogenetics
Epidemiologic methods

Publications

Publications:

Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with anti-hypertensive drug therapies [2]. JAMA 1995; 274: 620–625.
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis [3]. JAMA 2003; 289: 2534–2544.
Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation [4]. JAMA. 2008 Apr 16;299(15):1813–7.
Psaty BM, O’Donnell CJ, Gudnason V, Kunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JCM, Boerwinkle E on behalf of the CHARGE Consortiu. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts [5]. Circ Cardiovasc Genet 2009; 2: 73–80.
Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, … Psaty BM#, Abecasis GR#, Chakravarti A#, Elliott P#, van Duijn CM#, Newton-Cheh C#, Levy D#, Caulfield MJ#, Johnson T#. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk [6]. Nature. 2011 Sep 11;478(7367):103–9. #These authors contributed equally.